Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 329

1.

Chromosome 9p24 abnormalities: prevalence, description of novel JAK2 translocations, JAK2V617F mutation analysis and clinicopathologic correlates.

Patnaik MM, Knudson RA, Gangat N, Hanson CA, Pardanani A, Tefferi A, Ketterling RP.

Eur J Haematol. 2010 Jun;84(6):518-24. doi: 10.1111/j.1600-0609.2010.01428.x. Epub 2010 Mar 11.

PMID:
20331734
3.

Clonal analyses define the relationships between chromosomal abnormalities and JAK2V617F in patients with Ph-negative myeloproliferative neoplasms.

Wang X, LeBlanc A, Gruenstein S, Xu M, Mascarenhas J, Panzera B, Wisch N, Parker C, Goldberg JD, Prchal J, Hoffman R, Najfeld V.

Exp Hematol. 2009 Oct;37(10):1194-200. doi: 10.1016/j.exphem.2009.07.003. Epub 2009 Jul 15.

PMID:
19615425
4.
5.

[A quantitative assay for JAK2 mutation in 135 patients with chronic myeloproliferative neoplasms].

Chao HY, Shen YM, Zhang R, Feng YF, Cen JN, Yao L, Shen HJ, Zhu ZL, Xue YQ.

Zhonghua Xue Ye Xue Za Zhi. 2009 May;30(5):321-5. Chinese.

PMID:
19799128
6.

Association of JAK2 mutation status and cytogenetic abnormalities in myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms.

Dunlap J, Kelemen K, Leeborg N, Braziel R, Olson S, Press R, Huang J, Gatter K, Loriaux M, Fan G.

Am J Clin Pathol. 2011 May;135(5):709-19. doi: 10.1309/AJCPS6C8EVYCQNRM.

7.

Polycythemia vera transforming to acute myeloid leukemia and complex abnormalities including 9p homogeneously staining region with amplification of MLLT3, JMJD2C, JAK2, and SMARCA2.

Hélias C, Struski S, Gervais C, Leymarie V, Mauvieux L, Herbrecht R, Lessard M.

Cancer Genet Cytogenet. 2008 Jan 1;180(1):51-5.

PMID:
18068534
9.

Chronic idiopathic myelofibrosis (CIMF) resulting from a unique 3;9 translocation disrupting the janus kinase 2 (JAK2) gene.

Mark HF, Sotomayor EA, Nelson M, Chaves F, Sanger WG, Kaleem Z, Caughron SK.

Exp Mol Pathol. 2006 Dec;81(3):217-23. Epub 2006 Sep 7.

PMID:
16959246
10.

Myeloproliferative neoplasm induced by constitutive expression of JAK2V617F in knock-in mice.

Marty C, Lacout C, Martin A, Hasan S, Jacquot S, Birling MC, Vainchenker W, Villeval JL.

Blood. 2010 Aug 5;116(5):783-7. doi: 10.1182/blood-2009-12-257063. Epub 2010 May 14.

11.

Chromosome 8p11.2 translocations: prevalence, FISH analysis for FGFR1 and MYST3, and clinicopathologic correlates in a consecutive cohort of 13 cases from a single institution.

Patnaik MM, Gangat N, Knudson RA, Keefe JG, Hanson CA, Pardanani A, Ketterling RP, Tefferi A.

Am J Hematol. 2010 Apr;85(4):238-42. doi: 10.1002/ajh.21631.

12.

The role of Janus Kinase 2 V617F mutation in extramedullary hematopoiesis of the spleen in neoplastic myeloid disorders.

Hsieh PP, Olsen RJ, O'Malley DP, Konoplev SN, Hussong JW, Dunphy CH, Perkins SL, Cheng L, Lin P, Chang CC.

Mod Pathol. 2007 Sep;20(9):929-35. Epub 2007 Jul 20.

13.

[Detection and clinical significance of JAK2 mutation in 412 patients with chronic myeloproliferative neoplasms].

Chao HY, Fan Z, Zhang R, Shen YM, Chen W, Fei HR, Zhu ZL, Feng YF, Chen ZX, Xue YQ.

Zhonghua Zhong Liu Za Zhi. 2009 Jul;31(7):510-4. Chinese.

PMID:
19950698
14.

[Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].

Rajnai H, Bödör C, Reiniger L, Timár B, Csernus B, Szepesi A, Csomor J, Matolcsy A.

Orv Hetil. 2006 Nov 12;147(45):2175-9. Hungarian.

PMID:
17402211
15.

Recurrent der(9;18) in essential thrombocythemia with JAK2 V617F is highly linked to myelofibrosis development.

Ohyashiki K, Kodama A, Ohyashiki JH.

Cancer Genet Cytogenet. 2008 Oct;186(1):6-11. doi: 10.1016/j.cancergencyto.2008.04.021.

PMID:
18786436
16.

Different involvement of the megakaryocytic lineage by the JAK2 V617F mutation in Polycythemia vera, essential thrombocythemia and chronic idiopathic myelofibrosis.

Hussein K, Brakensiek K, Buesche G, Buhr T, Wiese B, Kreipe H, Bock O.

Ann Hematol. 2007 Apr;86(4):245-53. Epub 2007 Jan 30.

PMID:
17262192
17.

Clinical Manifestations and Risk Factors for Complications of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.

Duangnapasatit B, Rattarittamrong E, Rattanathammethee T, Hantrakool S, Chai-Adisaksopha C, Tantiworawit A, Norasetthada L.

Asian Pac J Cancer Prev. 2015;16(12):5013-8.

18.

The JAK2V617F mutation in polycythemia vera and other myeloproliferative disorders: one mutation for three diseases?

James C.

Hematology Am Soc Hematol Educ Program. 2008:69-75. doi: 10.1182/asheducation-2008.1.69. Review.

PMID:
19074061
19.

Oligonucleotide array CGH studies in myeloproliferative neoplasms: comparison with JAK2V617F mutational status and conventional chromosome analysis.

Tefferi A, Sirhan S, Sun Y, Lasho T, Finke CM, Weisberger J, Bale S, Compton J, LeDuc CA, Pardanani A, Thorland EC, Shevchenko Y, Grodman M, Chung WK.

Leuk Res. 2009 May;33(5):662-4. doi: 10.1016/j.leukres.2008.09.009. Epub 2008 Oct 19.

PMID:
18937974
20.

The t(8;9)(p22;p24) translocation in atypical chronic myeloid leukaemia yields a new PCM1-JAK2 fusion gene.

Bousquet M, Quelen C, De Mas V, Duchayne E, Roquefeuil B, Delsol G, Laurent G, Dastugue N, Brousset P.

Oncogene. 2005 Nov 3;24(48):7248-52.

PMID:
16091753
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk